finerenone
Sep 27, 2024
Pooled Analysis of Finerenone Presented at EASD 2024, Poised to Strengthen its Position in the Cardio-Kidney-Metabolic Market Further
Data from an integrated pooled analysis of finerenone across three Phase III trials involving heart failure, chronic kidney disease (CKD), and Type 2 diabetes (T2D) was presented at the 2024 European Association for the Study of Diabetes (EASD) Congress. This analysis was conducted with data from the FIDELIO-DKD2 a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
